申请人:Merck Sharp & Dohme Limited
公开号:US06303597B1
公开(公告)日:2001-10-16
1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position, a substituted alkoxy moiety at the 6-position, and an optionally substituted bicycloalkyl ring system at the 7-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, are useful in the treatment of anxiety and convulsions.
1,2,4-三唑[4,3-b]吡啶衍生物,在3位具有可选取代的环烷基,苯基或杂环芳基取代基,在6位具有取代的烷氧基,以及在7位具有可选取代的双环烷基环系统,是GABAA受体的选择性配体,特别是具有高亲和力的α2和/或α3亚基,可用于治疗焦虑和惊厥。